"Vandaag de cijfers van Gilead"
Wall Street renowned brokerages following Gilead Sciences, Inc. (NASDAQ:GILD) have now given a mean price target of $105 on its stock. After accomplishing a methodical study, the analysts have specified a target price range.
The intense high range is put at $120 while the lowest price is $88. It is the mean price reached following the Zacks poll. In addition to this price estimate, the leading brokerages have announced the earnings estimates for Gilead Sciences, Inc. (NASDAQ:GILD).
For the quarter, the forecasted EPS stands at $2.74 for Gilead Sciences, Inc. (NASDAQ:GILD). The report is likely to be publicized on or around 2016-11-01. As per the latest update, the firm’s EPS came at $3.03 for the period ended 2016-06-30.
Zacks study examines the projections given by renowned brokerages in the industry. The hold, buy and sell recommendations are compiled to get an average rating on a 1-5 scale. It is a reducing scale, which can be conveniently decoded by shareholders. Brokers deploy unique mechanisms to get individual Buy/Sell references.
On the contrary, Zacks gets a consensus analyst rating on the stock. Value scores approaching towards 1 means a buy recommendation and rating of 5 is considered bearish for stock. Gilead Sciences, Inc. (NASDAQ:GILD)’s rating score is 1.95 based on 13 stock views.
Gilead Sciences, Inc. (NASDAQ:GILD) probably will achieve EPS of $10.41 in next year. The experts have a positive EPS target of $10.7 for the company while the lowest estimate for the year is set at $10.01 year.